BioInvent International

BioInvent inks agreement with Cancer Research U.K., CRT and LLR

Wednesday, January 21, 2015

BioInvent International, a research-based pharmaceutical company based in Sweden, has reached an agreement with Cancer Research U.K.Cancer Research Technology (CRT), the charity’s development and commercialization arm, and Leukemia & Lymphoma Research (LLR) to take its investigational drug, BI-1206, into a collaborative phase I/II trial for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

[Read More]

BioInvent focuses its business, reduces staff

Tuesday, October 2, 2012

Sweden-based BioInvent International has decided to focus its operations with the aim of achieving self-financing of the business before external costs for future new clinical studies. Its development of proprietary antibody drugs will concentrate primarily on developing new cancer drugs, resulting in a clear indication focus. The company currently has five agreements with major companies based on products from the antibody library, n-CoDeR. It will increase the efforts to create new n‑CoDeR agreements for clinical programs and continue to develop existing partnerships.

[Read More]